Geron triumphs in FDA AdComm battle, securing 12-2 vote in favor of blood cancer drug imetelstat - Fierce Biotech

1. Geron triumphs in FDA AdComm battle, securing 12-2 vote in favor of blood cancer drug imetelstat  Fierce Biotech
2. Geron Stock Is Soaring After Hours: What's Going On?  Yahoo Finance
3. Geron’s stock soars 95% after FDA panel votes in favor of blood-disorder drug  MarketWatch
4. Imetelstat improves blood transfusion independence in lower-risk myelodysplastic syndromes  2 Minute Medicine
5. FDA ODAC Votes in Favor of Imetelstat Benefits Vs Risks in Lower-Risk MDS  Cancer Network